NCT05764395 2024-10-10
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
Vanderbilt-Ingram Cancer Center
Phase 2 Suspended
Vanderbilt-Ingram Cancer Center
ImmVira Pharma Co. Ltd
University of California, Davis
University Hospital, Geneva
University of Virginia
Anosys